-
Mashup Score: 26New model shows cortical implants like Elon Musk's Blindsight are unlikely to 'exceed normal human vision' - 11 month(s) ago
Elon Musk recently declared on X that Blindsight, a cortical implant to restore vision, would have low resolution at first “but may ultimately exceed normal human vision.”
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 25
A group of researchers from Chalmers University of Technology in Sweden, University of Freiburg and the Netherlands Institute for Neuroscience have created an exceptionally small implant with electrodes …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet-
Researchers report exceptionally small implant for future #vision correction https://t.co/A6iR2RH0to
-
-
Mashup Score: 0
By 2040, the number of blindness and vision loss cases are estimated to increase by roughly 50% across Brazil, Russia, India, China, and South America, a new study found.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Blindness and #vision loss burdens is projected to increase in Brazil, Russia, India, China, and South Africa by 2040, according to a new study led by Jianqi Chen, MD, @SunYatsen_Uni. https://t.co/2woNmH2jjN https://t.co/WxJyM4Vc3X
-
-
Mashup Score: 3From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi - 2 year(s) ago
In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death….
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
From the #VISION trial: Improved patient outcomes with lutetium-PSMA-617. Karim Fizazi, MD, PhD @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on the quality of life outcomes from the VISION trial, published in @TheLancetOncol > https://t.co/oyV97QM19P https://t.co/cadr2QUlty
-
-
Mashup Score: 0Assessing Reader Variability in PSMA-PET/CT Scan Interpretation: A Substudy of the VISION Trial, Journal Club - Rashid Sayyid & Zachary Klaassen - 2 year(s) ago
Rashid Sayyid and Zach Klaassen analyze an ad hoc analysis from the VISION study, published in the Journal of Nuclear Medicine. The study investigates the agreement between readers in the interpretation of 68Ga-PSMA-11 PET/CT scans to determine patient eligibility for 177Lu-PSMA-617 Radioligand Therapy in the treatment of prostate cancer. They elaborate on the study’s methodology, including the…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Assessing reader variability in PSMA-PET/CT scan interpretation: a substudy of the #VISION trial. A #JournalClub discussion with @RKSayyid @UofT & @zklaassen_md @GACancerCenter on UroToday > https://t.co/AZFPcAgcNz https://t.co/TmhOwlc9am
-
-
Mashup Score: 2
Rashid Sayyid and Zach Klaassen, dissect a publication from the VISION study regarding health-related quality of life and pain outcomes with Lu-PSMA-617+ Standard of Care versus Standard of Care alone in patients with mCRPC. This study, conducted across 84 global centers, reveals that the addition of Lu-PSMA-617 to standard care significantly improved overall survival rates from 11.3 to 15.3…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Improving #mCRPC outcomes: #VISION Study highlights Lu-PSMA-617's impact on survival and QoL. @RKSayyid @UofT & @zklaassen_md @GACancerCenter join in this #JournalClub discussion on UroToday > https://t.co/l4Hs32h5c1 @TheLancetOncol https://t.co/S1bsIsvuX0
-
-
Mashup Score: 0From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi - 2 year(s) ago
In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death….
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
From the #VISION trial: Improved patient outcomes with lutetium-PSMA-617. Karim Fizazi, MD, PhD @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on the quality of life outcomes from the VISION trial, published in @TheLancetOncol > https://t.co/oyV97QM19P https://t.co/UFdx1EXG0m
-
-
Mashup Score: 0LASIK Enhancements: Handle with Care - 2 year(s) ago
D espite LASIK’s accuracy, enhancements simply come with the territory. E very once in a while a target is missed or a patient from years ago will show up with visual complaints and refractive surgeons must consider time, technique and potential risks of retreatment. We asked some veteran refractive surgeons for their insight and pearls for these rare but unavoidable situations. Enhancements typically fall into two categories: early and late. Early enhancements take place within the first few months of
Source: www.reviewofophthalmology.comCategories: Latest Headlines, OphthalmologyTweet-
LASIK Enhancements: Handle with Care Refractive surgeons say the keys to managing these cases are patience and precision. https://t.co/c6k5HV4Hfw #ophthalmology #eyecare #eyesurgeon #eyesurgery #LASIK #refractivesurgery #ophthalmologist #vision https://t.co/08OpJQfK7o
-
-
Mashup Score: 6Assessing Reader Variability in PSMA-PET/CT Scan Interpretation: A Substudy of the VISION Trial, Journal Club - Rashid Sayyid & Zachary Klaassen - 2 year(s) ago
Rashid Sayyid and Zach Klaassen analyze an ad hoc analysis from the VISION study, published in the Journal of Nuclear Medicine. The study investigates the agreement between readers in the interpretation of 68Ga-PSMA-11 PET/CT scans to determine patient eligibility for 177Lu-PSMA-617 Radioligand Therapy in the treatment of prostate cancer. They elaborate on the study’s methodology, including the…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Assessing reader variability in PSMA-PET/CT scan interpretation: a substudy of the #VISION trial. A #JournalClub discussion with @RKSayyid @UofT & @zklaassen_md @GACancerCenter on UroToday > https://t.co/AZFPcAgcNz https://t.co/4b7jCizkCO
-
-
Mashup Score: 0From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi - 2 year(s) ago
In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death….
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
From the #VISION trial: Improved patient outcomes with lutetium-PSMA-617. Karim Fizazi, MD, PhD @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on the quality of life outcomes from the VISION trial, published in @TheLancetOncol > https://t.co/oyV97QM19P https://t.co/5U0crvs6KA
-
New model shows cortical implants like Elon Musk's Blindsight are unlikely to 'exceed normal human #vision' @SciReports https://t.co/DkiaJXPyZN